CYBERJAYA, April 12 (Bernama) — Hematogenix, the first central oncology clinical trials lab in Malaysia, brings the nation a step closer to making it the preferred destination in the region for clinical research. The facility in Cyberjaya, which was visited earlier today by the Minister of Health YB Khairy Jamaluddin, has been operational since June 2021, providing specialized services for cancer research.
Hematogenix is the sole facility within the Asia Pacific region to be CAP (College of American Pathologists) accredited and CLIA (Clinical Laboratory Improvement Amendments) certified. Its strategic location positions Malaysia as a hub for the Asia Pacific region in providing highly specialized central laboratory support in clinical research. Hematogenix Malaysia offers an exclusive scope of services within the region,that are often sought for by organizations conducting clinical trials. Currently the facility is managing at least 10 clinical studies from multinational global pharmaceutical companies and has processed over 800 shipments of biological specimens delivered to their facility in Cyberjaya from study sites across Asia Pacific namely Japan, South Korea, Taiwan, and Australia.
